Acrivon Therapeutics, Inc. Logo

Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):
US0048901096
LEI:
Country:
United States of America
Address:
480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Heidelberg Pharma AG Logo
Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.
Germany HPHA
HighCo Logo
Data marketing firm offering digital solutions for brands & retailers to influence shopper behavior.
France HCO
HireQuest, Inc. Logo
A franchisor of staffing solutions offering temporary labor and skilled placement to diverse industries.
United States of America HQI
H.I.S. Co., Ltd. Logo
A major Japanese travel agency providing global tour packages, lodging, and transport.
Japan 9603
Hit Co., Ltd. Logo
Specialized OOH advertising firm providing digital & static billboards in high-visibility areas.
Japan 378A
HLB Therapeutics Co.,Ltd. Logo
Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.
South Korea 115450
HONYAKU Center Inc. Logo
Provides industrial translation and interpreting for patent, legal, and corporate clients.
Japan 2483
A holding company for advanced materials, AI/data solutions, mobility, and global logistics.
South Korea 487570
Human Metabolome Technologies, Inc. Logo
A leader in metabolomics, providing CE-MS analysis to support R&D in biotech, pharma, and food.
Japan 6090
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France ALHYG

Talk to a Data Expert

Have a question? We'll get back to you promptly.